Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Newest Viral Hepatitis Data From AASLD 2022

Source: Clinical Impact of New Viral Hepatitis Data From AASLD 2022*
November 4-8, 2022; Washington, DC
Listen to expert insights from Stefan Zeuzem, MD, on updates and new viral hepatitis data from AASLD 2022, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and HCC risk reduction with use of DAAs.
Stefan Zeuzem, MD
Released: December 6, 2022

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:

  • Hepatitis B
    • Prevention of HBV vertical transmission when HBIg is unavailable
    • Therapeutic vaccination for HBV cure
    • Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
  • Hepatitis delta
    • HDV prevalence in ethnically diverse, urban, safety-net populations
    • Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
    • Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
    • HDV functional cure with lonafarnib-based therapy
  • Hepatitis C
    • Integrated community HCV service for PWUD: the ITTREAT study
    • Helios-3 study of treatment of people with HCV by specialists or nonspecialists
    • Risk of HCC after SVR in patients with HCV

Information on this Educational Activity

Faculty

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD: consultant/advisor/speaker: AbbVie, BioMarin, Gilead Sciences, GlaxoSmithKline, Intercept, Janssen, MSD/Merck, Novo Nordisk, SoBi.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings